SINGAPORE, July 14 — A securities fraud class action has been filed against ADMA Biologics, naming the company and two of its top executives as defendants, in a case that is drawing attention from investors across Asia who hold shares in the US-listed biopharmaceutical firm. The lawsuit specifically names Chief Executive Officer Adam Grossman, who has led ADMA since 2014, and Chief Financial Officer Brian Lenz, who has served since 2016. The legal action alleges that these executives made false and misleading statements concerning the company’s sales practices and revenue.
For communities of investors in the Philippines, Singapore, and other Asian markets who have purchased ADMA securities during the defined class period, this case raises questions about the reliability of information coming from US-listed healthcare companies. Many family offices and retail investors across the region have increasingly allocated capital to American biotech stocks, drawn by the sector’s growth potential.
Legal firms leading the charge
The case is being handled by several prominent securities litigation firms, including the Rosen Law Firm and Pomerantz LLP, both of which specialize in shareholder lawsuits. These firms have a track record of pursuing claims against corporations for alleged securities law violations. The plaintiffs are represented by attorneys who have previously won settlements in landmark cases, including In re: Enron Corp. Securities Litigation from 2001 and In re: WorldCom Securities Litigation from 2002.
Those cases, which involved massive corporate accounting scandals, resulted in significant recoveries for defrauded investors and reshaped corporate governance standards in the United States. The lead plaintiff in the ADMA case is expected to be an institutional investor or a group of investors who suffered substantial losses from their investments in the company’s securities.
This is a standard procedure in securities class actions, where the court appoints the investor or group with the largest financial stake to represent the class.
What this means for investors
The lawsuit seeks to recover damages for investors who purchased ADMA securities during the class period. For Asian investors, the case underscores the importance of understanding the legal mechanisms available when companies are accused of misleading the market. Securities fraud class actions allow investors to band together to seek compensation when they have been harmed by false or misleading statements that artificially inflated stock prices.
When the truth emerges, share prices often fall, leaving investors with losses. The ADMA Biologics case is still in its early stages.
The court will need to certify the class, and the defendants will have the opportunity to respond to the allegations. Investors who purchased ADMA securities during the class period should monitor the case closely, as deadlines for filing lead plaintiff motions will be established by the court. Closer to home, this case serves as a reminder for Asian investors in US equities to stay informed about the legal proceedings that can affect the value of their holdings.
The outcome of the ADMA lawsuit could set a precedent for how similar cases involving biotech companies are handled in the future.
